Limits...
Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Fan M, He X, Xu X - Mol Med Rep (2015)

Bottom Line: Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies.As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma.In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.

ABSTRACT
Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

Show MeSH

Related in: MedlinePlus

Low expression levels of TET1 were detected in the ACHN renal carcinoma cell line, which was accompanied by increased proliferation and migration abilities. (A) Protein levels of TET1 in the ACHN and 293T cells. ACHN is a renal carcinoma cell line and 293T is an embryonic kidney-derived cell line. (B) Proliferation abilities of the ACHN and 293T cells. (C) Metastatic abilities of ACHN and 293T cells were determined using a migration assay. Representative images and quantification are shown. *P<0.05, compared with 293T cells. TET1, ten-eleven translocation methylcytosine dioxygenase 1; OD, optical density.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4581741&req=5

f3-mmr-12-04-4837: Low expression levels of TET1 were detected in the ACHN renal carcinoma cell line, which was accompanied by increased proliferation and migration abilities. (A) Protein levels of TET1 in the ACHN and 293T cells. ACHN is a renal carcinoma cell line and 293T is an embryonic kidney-derived cell line. (B) Proliferation abilities of the ACHN and 293T cells. (C) Metastatic abilities of ACHN and 293T cells were determined using a migration assay. Representative images and quantification are shown. *P<0.05, compared with 293T cells. TET1, ten-eleven translocation methylcytosine dioxygenase 1; OD, optical density.

Mentions: The expression of TET1 was low in the ACHN renal carcinoma cell line, which exhibited the ability to metastasize to the lungs. As shown in Fig. 3A, the protein expression level of TET1 in the ACHN cells was decreased, and was ~33.67% of the level detected in the 293T cells. In addition, the proliferation and migration abilities of the ACHN cells were increased, compared with 293T cells(Fig. 3B and C). These results indicated that low expression levels of TET1 improved the proliferation and migration abilities of the ACHN cells.


Restored expression levels of TET1 decrease the proliferation and migration of renal carcinoma cells.

Fan M, He X, Xu X - Mol Med Rep (2015)

Low expression levels of TET1 were detected in the ACHN renal carcinoma cell line, which was accompanied by increased proliferation and migration abilities. (A) Protein levels of TET1 in the ACHN and 293T cells. ACHN is a renal carcinoma cell line and 293T is an embryonic kidney-derived cell line. (B) Proliferation abilities of the ACHN and 293T cells. (C) Metastatic abilities of ACHN and 293T cells were determined using a migration assay. Representative images and quantification are shown. *P<0.05, compared with 293T cells. TET1, ten-eleven translocation methylcytosine dioxygenase 1; OD, optical density.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4581741&req=5

f3-mmr-12-04-4837: Low expression levels of TET1 were detected in the ACHN renal carcinoma cell line, which was accompanied by increased proliferation and migration abilities. (A) Protein levels of TET1 in the ACHN and 293T cells. ACHN is a renal carcinoma cell line and 293T is an embryonic kidney-derived cell line. (B) Proliferation abilities of the ACHN and 293T cells. (C) Metastatic abilities of ACHN and 293T cells were determined using a migration assay. Representative images and quantification are shown. *P<0.05, compared with 293T cells. TET1, ten-eleven translocation methylcytosine dioxygenase 1; OD, optical density.
Mentions: The expression of TET1 was low in the ACHN renal carcinoma cell line, which exhibited the ability to metastasize to the lungs. As shown in Fig. 3A, the protein expression level of TET1 in the ACHN cells was decreased, and was ~33.67% of the level detected in the 293T cells. In addition, the proliferation and migration abilities of the ACHN cells were increased, compared with 293T cells(Fig. 3B and C). These results indicated that low expression levels of TET1 improved the proliferation and migration abilities of the ACHN cells.

Bottom Line: Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies.As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma.In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, The First People's Hospital of Changzhou, Changzhou, Jiangsu 213003, P.R. China.

ABSTRACT
Renal carcinoma is the most common type of kidney cancer in adults and is responsible for ~90‑95% of the cases of kidney cancer. Ten‑eleven translocation methylcytosine dioxygenase 1 (TET1) is a member of the TET family of enzymes, and is expressed at low levels in multiple malignancies. In the present study, a series of experiments were designed and performed to investigate whether the expression of TET1 is clinically correlated with clinical outcomes in renal carcinoma, and to examine the associations between TET1 expression level and the proliferation and migration in renal carcinoma cells. As a result, TET1 was observed to exhibit markedly low expression levels in 54 tumor tissue samples from 54 patients with renal carcinoma. Furthermore, statistical analysis revealed a clinical correlation between low expression levels of TET1 and the prognosis of patients with renal carcinoma. When TET1 was overexpressed in renal carcinoma cells, the viability and invasive abilities of the cells were decreased, and the rate of apoptosis was increased. In conclusion, the results demonstrated that TET1 is involved in tumor inhibition in renal carcinoma by promoting cell apoptosis and inhibiting cell proliferation and invasion, which may be exploited as a novel therapeutic target in the treatment of renal carcinoma.

Show MeSH
Related in: MedlinePlus